CA2720450C — New formulations, tablets comprising such formulations, their use and process for their preparation
Assigned to Boehringer Ingelheim International GmbH · Expires 2017-01-03 · 9y expired
What this patent protects
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 in-hibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
USPTO Abstract
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 in-hibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.